

## Special Issue

# Influenza Vaccination for People with Chronic Diseases

### Message from the Guest Editors

The effect of influenza vaccination on decreasing the risk of influenza virus infection has been well reported before. Moreover, via the protection from the influenza vaccine, the risk of mortality and other complications of influenza virus infection could be significantly lowered. Therefore, it is highly recommended to receive the influenza vaccine annually, especially for high-risk populations such as patients with chronic diseases, the elderly, and healthcare providers. In addition to the protective effect from infection, the other potential benefits of influenza vaccination have also been demonstrated in previous research. However, detailed mechanism and clinical data on the additional effects of influenza vaccination among patients with chronic diseases are still lacking. We are pleased to invite you to submit research articles regarding the effectiveness and potential mechanism of the influenza vaccine among patients with chronic diseases. Clinical observational studies, randomized control trials, and basic molecular/animal investigation are all welcome for submission.

---

### Guest Editors

Prof. Dr. Ju-Chi Liu

Dr. Wen-Rui Hao

Dr. Chun-Chao Chen

---

### Deadline for manuscript submissions

closed (25 May 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/134407](https://mdpi.com/si/134407)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).